Abbott Kaletra Tops 12% Of PI Market; Synthroid Outlook Is "Very Good"
Abbott expects to claim the number one spot in the protease inhibitor market by the end of 2001 on the strength of the first-year performance of Kaletra (ritonavir/lopinavir).
Abbott expects to claim the number one spot in the protease inhibitor market by the end of 2001 on the strength of the first-year performance of Kaletra (ritonavir/lopinavir).